DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $88,318,320 | -67.3% | 367,993 | -65.7% | 0.22% | -71.3% |
| Q1 2023 | $270,287,444 | +297.9% | 1,072,399 | +319.1% | 0.77% | +262.9% |
| Q4 2022 | $67,923,367 | +47.8% | 255,909 | +43.8% | 0.21% | +35.7% |
| Q3 2022 | $45,951,000 | +29.9% | 177,907 | +27.5% | 0.16% | +35.3% |
| Q2 2022 | $35,385,000 | +1446.5% | 139,573 | +1689.4% | 0.12% | +1557.1% |
| Q1 2022 | $2,288,000 | -97.8% | 7,800 | -97.5% | 0.01% | -96.9% |
| Q4 2021 | $104,247,000 | -45.2% | 316,848 | -49.3% | 0.22% | -47.5% |
| Q3 2021 | $190,269,000 | +470.7% | 624,978 | +322.0% | 0.42% | +388.5% |
| Q1 2021 | $33,337,000 | -39.0% | 148,111 | -39.8% | 0.09% | -44.6% |
| Q4 2020 | $54,635,000 | -70.8% | 245,949 | -71.7% | 0.16% | -76.3% |
| Q3 2020 | $186,851,000 | +3857.0% | 867,742 | +3149.4% | 0.66% | +2782.6% |
| Q2 2020 | $4,722,000 | +822.3% | 26,705 | +621.8% | 0.02% | +475.0% |
| Q1 2020 | $512,000 | +28.3% | 3,700 | +42.3% | 0.00% | +300.0% |
| Q4 2019 | $399,000 | -97.6% | 2,600 | -97.7% | 0.00% | -98.2% |
| Q3 2019 | $16,662,000 | +931.7% | 115,360 | +920.9% | 0.06% | +1000.0% |
| Q2 2019 | $1,615,000 | +130.7% | 11,300 | +113.2% | 0.01% | +150.0% |
| Q1 2019 | $700,000 | -99.1% | 5,300 | -99.3% | 0.00% | -99.0% |
| Q3 2018 | $76,814,000 | +139.5% | 706,922 | +117.5% | 0.21% | +117.7% |
| Q2 2018 | $32,066,000 | +159.4% | 324,954 | +157.4% | 0.10% | +134.1% |
| Q1 2018 | $12,363,000 | -85.0% | 126,265 | -85.8% | 0.04% | -84.8% |
| Q4 2017 | $82,492,000 | -20.4% | 888,730 | -26.5% | 0.27% | -26.7% |
| Q3 2017 | $103,653,000 | -14.6% | 1,208,354 | -16.0% | 0.37% | -16.4% |
| Q2 2017 | $121,421,000 | +10181.2% | 1,438,816 | +10319.4% | 0.44% | +10875.0% |
| Q1 2017 | $1,181,000 | -94.2% | 13,809 | -94.7% | 0.00% | -94.9% |
| Q4 2016 | $20,282,000 | -44.1% | 260,569 | -43.7% | 0.08% | -40.5% |
| Q3 2016 | $36,265,000 | +9674.9% | 462,625 | +12478.2% | 0.13% | +6450.0% |
| Q2 2016 | $371,000 | -65.6% | 3,678 | -67.6% | 0.00% | -60.0% |
| Q1 2016 | $1,077,000 | -17.2% | 11,353 | -18.9% | 0.01% | -16.7% |
| Q4 2015 | $1,300,000 | -92.6% | 14,000 | -93.2% | 0.01% | -93.3% |
| Q3 2015 | $17,566,000 | -45.6% | 206,151 | -45.8% | 0.09% | -43.4% |
| Q1 2015 | $32,272,000 | +195.3% | 380,123 | +164.3% | 0.16% | +224.5% |
| Q3 2014 | $10,928,000 | -82.4% | 143,821 | -82.7% | 0.05% | -85.3% |
| Q1 2014 | $62,184,000 | – | 829,113 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |